Company profile
ALTIMMUNE, INC.
NASDAQ:ALTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALT-801 | phase2 | — | 5 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04561245 | phase1 | completed | 2020-11-10 | 2021-10-29 | Altimmune, Inc. | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability |
| NCT05006885 | phase1 | completed | 2021-09-30 | 2022-08-17 | Altimmune, Inc. | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) |
| NCT05134662 | phase1 | completed | 2022-02-01 | 2023-02-03 | Altimmune, Inc. | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) |
| NCT05295875 | phase2 | completed | 2022-03-31 | 2023-09-28 | Altimmune, Inc. | Efficacy and Safety of ALT-801 in the Treatment of Obesity |
| NCT05292911 | phase1 | completed | 2022-03-09 | 2022-10-31 | Altimmune, Inc. | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) |
FDA applications (0)
No records yet.